Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Merck & Company today and set a price target of $120.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason Gerberry has given his Buy rating due to a combination of factors that suggest Merck & Company’s stock is poised for growth. The company is expected to execute well on both its existing product lines and its promising pipeline, with several drugs showing significant sales potential. Despite the anticipated loss of exclusivity for Keytruda, the impact is expected to be minimal and temporary, with growth resuming shortly thereafter.
Furthermore, Merck’s upcoming product launches, including Keytruda QLEX and Winrevair, are projected to drive substantial revenue growth. The company’s pipeline is robust, with key drugs like Welireg and TL1a showing potential for significant market impact. Overall, Merck’s financial outlook for FY26 is strong, with expected revenue and earnings growth that surpasses consensus estimates, making it an attractive investment opportunity.
In another report released on December 10, HSBC also maintained a Buy rating on the stock with a $120.00 price target.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRK in relation to earlier this year.